Close Menu

neurodegenerative disease

British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.

Quanterix said that the acquisition will secure the supply of neurofilament light antibodies that are critical to its Simoa assays and services.

The funding is being provided to a number of early-career investigators and collaborative research groups using genomics and other technologies.

Silicon Valley VC firm DFJ led the investment in Verge, which is applying machine learning to the development of new drugs for Parkinson's and ALS.

An analysis revealed an uptick in cancer in frontotemporal lobar degeneration-affected families with tau mutations, pointing to a broader tau protein role.

Using large-scale GWAS data, researchers saw shared genetic contributors for ALS and frontotemporal dementia, as well as ALS and progressive supranuclear palsy.

Q-State Biosciences, which focuses on neurologic disorders, will work closely with WuXi NextCode to relaunch Claritas' exome assays.

New research suggests that some risky and protective variants in the LRRK2 gene have shared genetic effects in Crohn's disease and Parkinson's disease.

The Boston-based hospitals will provide Berg access to clinically annotated patient-derived specimens to track neurological disease pathology and develop diagnostic tools.

The Martinos Center, Envision Genomics, and startup RowAnalytics are building an open precision medicine platform called Giro Health on IBM architecture.

Pages

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.